SEC Comment Letter for Fusion Pharmaceuticals Inc. (CIK 0001805890) — Jul 8, 2021
Fusion Pharmaceuticals Inc. (CIK 0001805890)
Date: July 8, 2021 · CIK: 0001805890 · Accession: 0000000000-21-008423
AI Filing Summary & Sentiment
File numbers found in text: 333-257653
Letter
United States securities and exchange commission logo July 8, 2021 John Valliant, Ph.D. Chief Executive Officer Fusion Pharmaceuticals Inc. Two International Place, Suite 2310 Boston, MA 02110 Re:Fusion Pharmaceuticals Inc. Registration Statement on Form S-3 Filed July 2, 2021 File No. 333-257653 Dear Dr. Valliant: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mitchell S. Bloom, Esq.
Show Raw Text
United States securities and exchange commission logo
July 8, 2021
John Valliant, Ph.D.
Chief Executive Officer
Fusion Pharmaceuticals Inc.
Two International Place, Suite 2310
Boston, MA 02110
Re:Fusion Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed July 2, 2021
File No. 333-257653
Dear Dr. Valliant:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mitchell S. Bloom, Esq.